BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perdrizet J, Santana CFS, Senna T, Alexandre RF, Sini de Almeida R, Spinardi J, Wasserman M. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother 2021;17:1162-72. [PMID: 32966176 DOI: 10.1080/21645515.2020.1809266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Perdrizet J, Horn E, Nua W, Perez-Peralta J, Nailes J, Santos J, Ong-Lim A. Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants". Infect Dis Ther 2022. [PMID: 35575973 DOI: 10.1007/s40121-022-00641-9] [Reference Citation Analysis]
2 Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman MD. Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium. Infect Dis Ther 2021;10:1765-78. [PMID: 34250576 DOI: 10.1007/s40121-021-00485-9] [Reference Citation Analysis]
3 Gómez JA, Pinto TJP, Guevara JN, Noronha TG. Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants". Hum Vaccin Immunother 2021;:1-3. [PMID: 34010099 DOI: 10.1080/21645515.2021.1894898] [Reference Citation Analysis]